All In Biotech

BLA 761238 · Tg Therapeutics, INC

Briumvi

Ublituximab-Xiiy · Intravenous · CD20-directed Cytolytic Antibody

Novel

CDER novel approval, Dec 28, 2022: To treat relapsing forms of multiple sclerosis

Last checked: Nov 20, 2026Latest source record: Jan 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Dec 28, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

46

11 Phase 3, 13 recruiting

FAERS reports

3,894

932 serious, 67 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 19, 2026.

BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BRIUMVI is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 , 14 ).

Mechanism: The precise mechanism by which ublituximab-xiiy exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ublituximab-xiiy results in cell lysis through mechanisms including antibody-dependent cellular cytolysis and complement-dependent cytolysis.

Therapeutic areas: Hematology and blood cancers · Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 28, 2022 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
  • BRIUMVI · UBLITUXIMAB-XIIY 25 MG/ML · INJECTABLE, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ublituximab" as an intervention, any sponsor and status, largest first.

All 46 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • infusion related reaction1,435
  • fatigue238
  • headache124
  • malaise116
  • pain109
  • urinary tract infection103
  • illness100
  • multiple sclerosis relapse99
  • asthenia94
  • gait disturbance90
  • inappropriate schedule of product administration88
  • maternal exposure during pregnancy82

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20153
20162
20172
201810
20191
202148
202226
2023247
20241,012
20251,783
2026760

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Briumvi (Ublituximab-Xiiy)

2024 spending

$8.0M

Beneficiaries

155

301 claims

Per beneficiary

$51,582

$1,752.86 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$1,791,742
2024$7,995,163

Part B: Briumvi (Ublituximab-Xiiy) · HCPCS J2329

2024 spending

$25.5M

Beneficiaries

518

1,120 claims

Per beneficiary

$49,274

2024 ASP limit $68.60 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$4,963,901
2024$25,523,924

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 23 on PubMed

Sponsor: Tg Therapeutics, INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.